Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Controlling pain is fundamental during and after surgical procedures. This study examines pain associated with robotic assisted surgery on prostate cancer or a kidney mass. In recent years, the risk of opioids in the postoperative period has gained interest due to the growing epidemic of addiction, dependence, and overdose. In this study, the investigators expect a continuous infusion of intravenous lidocaine during the perioperative period to result in less pain and less opioid use.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Missouri-Columbia
• Treatments: Lidocaine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Undergoing robotic assisted prostatectomy or robotic assisted partial nephrectomy at University of Missouri Hospital for prostate cancer or kidney mass

• Age ≥ 18 years

• ASA I-III

Exclusion Criteria:

• Inability to obtain written informed consent

• Allergy to lidocaine or other amide local anesthetics

• Atrioventricular conduction blocks

• CV instability and concomitant use of alpha agonists or beta blockers

• Recent myocardial infarction (≤ 6 months ago)

• Cardiac arrhythmia disorders

• Stokes-Adams syndrome

• Wolff-Parkinson-White syndrome

• Seizure disorders

• Liver failure or hepatic dysfunction

• Significant renal disease with a serum creatinine ≥ 2 mg/dl

• A family history of malignant hyperthermia

• Current use of opioids or documented history of opioid abuse

• Typically, have less than 3 bowel movement per week

• Combined surgical cases that include robotic prostatectomy or robotic partial nephrectomy